EMA will not set a 50% efficacy threshold for the covid-19 vaccine

The European Medical Agency (EMA) said on Thursday that it will not impose a 50% vaccine efficacy threshold, adding that EU countries should use all available vaccines to fight the pandemic. https://www.eudebates.tv/debates/eu-policies/health-eu-policies/ursula-von-der-leyen-admits-to-failings-in-vaccine-eu-plan/ The German biotech company CureVac announced that its covid-19 vaccine is only 47% effective in the later stages of the trial, which may provide hundreds of millions of doses to the European Union. #eudebates #Covid_19 #Corona #COVD19 #Health #COVID #vaccine According to Reuters, as CureVac’s sole and major customer so far, the European Union ordered about 405 million doses of vaccine in November, and subsequently signed a memorandum of understanding with Germany to provide another 20 million doses of vaccine. Marco Cavalieri, head of EMA’s Department of Biological Threats and Vaccination Strategies, said: “We need to collect all the final data of this clinical trial and conduct a good analysis of the results of different regions, age groups and different variants.”. “So I think it’s too early to discuss what this means… We always think it’s difficult to define a threshold in advance,” he said at the press conference, adding that the EMA will pay special attention to possible spread The variants are more contagious. . In the United States, the Food and Drug Administration requires the covida-19 vaccine to show at least 50% efficacy before it can be approved in a critical testing phase. Last November, before the first batch of vaccine trial data came out, EMA stated that it would not set a minimum level of effectiveness for potential COVID vaccines. Cavalleri also stated that EU countries in the midst of a pandemic should use all available options. Some countries have decided to restrict the use of vector vaccines, such as AstraZeneca and Johnson & Johnson, because this may be related to the occurrence of rare blood clots, and prefer the mRNA technology used by Pfizer and Moderna. He said: “We are still in a pandemic, and it is very important that we use all available…